Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule

Value in Health

Volumn 12, Issue 6, 2009, Pages 888-898

  Milne, Richard J ^a   Grimwood, Keith ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cost effectiveness; Gastroenteritis; Immunization; Rotavirus; Vaccine

Indexed keywords

ORAL POLIOMYELITIS VACCINE; ORAL REHYDRATION SOLUTION; ROTAVIRUS VACCINE;

ARTICLE; BUDGET; CAREGIVER; CHILD; CHILD HEALTH CARE; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EMERGENCY CARE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; IMMUNIZATION; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; NEW ZEALAND; ORAL REHYDRATION THERAPY; POLIOMYELITIS; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REPEATED DRUG DOSE; ROTAVIRUS; VACCINATION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GASTROENTERITIS; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; IMMUNIZATION SCHEDULE; INFANT; NEW ZEALAND; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 67651229443     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00534.x     Document Type: Article

References (59)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003 9 : 565 72.
2. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 12 : 304 6.
3. Lepage P. Rotavirus infection in Europe: time for effective prevention? Pediatr Infect Dis J 2006 25 (Suppl. 1 S5 6.
4. Fischer T, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993-2003. J Infect Dis 2007 195 : 1117 25.
5. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006 25 (Suppl. 1 S7 11.
6. Carlin JB, Chondros P, Masendycz P, et al. Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993-1996. Med J Aust 1998 169 : 252 6.
7. Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Aust N Z J Public Health 2006 30 : 416 21.
8. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: The REVEAL study. J Infect Dis 2007 195 (Suppl. 1 S4 16.
9. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006 6 : 805 12.
10. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 55 (RR12 1 13.
11. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 2008 27 (Suppl S20 7.
12. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine [see comment N Engl J Med 2006 354 : 23 33.
13. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis [see comment N Engl J Med 2006 354 : 11 22.
14. Haber P, Patel M, Izurieta H, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008 121 : 1206 12.
15. Fruhwirth M, Heininger U, Ehlken B, et al. International variation in disease burden of rotavirus gastroenteritis in children with community and nosocomially acquired infection. Pediatr Infect Dis J 2001 20 : 784 91.
16. Grimwood K, Buttery JP. Clinical update: rotavirus gastroenteritis and its prevention. Lancet 2007 370 : 302 4.
17. Anonymous. Mortality 2002 and 2003. Available from : http://www.nzhis. govt.nz/moh.nsf/indexns/stats Accessed 2007 K, Huang Q, Cohet C, et al. Rotavirus hospitalisation in New Zealand children under 3 years of age. J Pediatr Child Health 2006 42 : 196 203.
18. Barnes G, Uren E, Stevens K, Bishop R. Etiology of acute gastroenteritis in hospitalized children in Melbourne, Australia, from April 1980 to March 1993. J Clin Microbiol 1998 36 : 133 8.
19. Anonymous. The National Childhood Immunisation Coverage Survey 2005. Wellington : Ministry of Health, 2007.
20. Harris JP, Jit M, Cooper D, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007 25 : 3962 70.
21. Giaquinto C, Van Damme P, Huet F, et al. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007 195 (Suppl. 1 S36 44.
22. Dennehy P, Goveia M, Dallas M, Heaton P. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007 11 : 36 42.
23. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007 119 : 171 82.
24. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996 276 : 1253 8.
25. Ardern-Holmes SL, Lennon D, Pinnock R, et al. Trends in hospitalization and mortality from rotavirus disease in New Zealand infants. Pediatr Infect Dis J 1999 18 : 614 9.
26. Craig E, Jackson C, Han D. Monitoring the Health of New Zealand Children and Young People: Indicator Handbook. Aukland, New Zealand : Paediatric Society of New Zealand, 2007.
27. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008 26 : 706 15.
28. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007 25 : 8851 60.
29. Jit M, Pebody R, Chen M, et al. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccin 2007 3 : 23 6.
30. Senecal M, Brisson M, Lebed M. Burden of rotavirus associated gastroenteritis in Canadian families: a prospective community based study. Seventh Canadian Immunization Conference 2006.
31. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost effectiveness of vaccination. Vaccine 2007 25 : 3971 9.
32. Blackmore T, Buchan G, Grant C, et al. Immunisation Handbook 2006. Wellington : Ministry of Health, 2006.
33. Vesikari T, Karoven A, Ferrante S, et al. Efficacy of the Pentavalent Rotavirus Vaccine, RotaTeqTM, against Hospitalizations And Emergency Department Visits up to 3 Years Postvaccination: The Finnish Extension Study 13th International Congress on Infectious Diseases. Kuala, Lumpur, Malaysia, 2008.
34. Anonymous. New Zealand Pharmaceutical Schedule. Available from: http://www.pharmac.govt.nz/Schedule [Accessed November, 2008 Accessed November, 2007 SE, Elser J, Marchant C, et al. Impact of acute rotavirus gastroenteritis on pediatric outpatient practices in the United States. Pediatr Infect Dis J 2006 25 : 584 9.
35. Lee BP, Azimi PH, Staat MA, et al. Nonmedical costs associated with rotavirus disease requiring hospitalization. Pediatr Infect Dis J 2005 24 : 984 8.
36. Anonymous. Prescription for Pharmacoeconomic Analysis, Version 2. Wellington : HPARMAC, 2007.
37. Milne R. Valuing prevention: discounting health benefits and costs in New Zealand. N Z Med J 2005 118 : 1 4.
38. Vesikari T, Rautanen T, Von Bonsdorff CH. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr 1999 88 (Suppl S24 30.
39. Ryan MJ, Ramsay M, Brown D, et al. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996 174 (Suppl. 1 S12 8.
40. Ferson MJ. Hospitalisations for rotavirus gastroenteritis among children under five years of age in New South Wales. Med J Aust 1996 164 : 273 6.
41. Chandran A, Heinzen R, Santosham M, Siberry S. Nosocomial rotavirus infections: a systematic review. J Pediatr 2006 149 : 441 7.
42. Lieberman J, Huang X, Koski E, et al. Decline in Rotavirus cases in the US after Licensure of a Live, Oral Rotavirus Vaccine. 46th Annual Meeting, Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC : Infectious Diseases Society of America, 2008. p. G1-437.
43. Daskalaki I, Wood S, Inumerable Y, Long S. Epidemiology of Rotavirus-Associated Hospitalizations Pre- and Post-Implementation of Immunization: North Philadelphia. 2000-2008. 46th Annual Meeting, Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America. Washington, DC, 2008. p. G1-432.
44. Walker DG, Rheingans R. Cost-effectiveness of rotavirus vaccines. Expert Rev Pharmacoeconomics Outcomes Res 2005 5 : 593 601.
45. Carlin JB, Jackson T, Lane L, et al. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999 23 : 611 6.
46. Ho A-H, Nelson E, Walker D. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008 93 : 52 8.
47. Widdowson M-A, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007 119 : 684 97.
48. Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in The Netherlands. Vaccine 2008 26 : 1118 27.
49. Grimwood K, Abbott GD, Fergusson DM, et al. Spread of rotavirus within families: a community based study. Br Med J (Clin Res Ed) 1983 287 : 575 7.
50. Fischer TK, Molbak K. The costs of an outbreak - an example from a Danish day care setting. Vaccine 2001 20 : 637 8.
51. Lopman BA, Reacher MH, Vipond IB, et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. Emerg Infect Dis 2004 10 : 1827 34.
52. Mast T, Wang F, Goli V, et al. Post-Licensure Effectiveness of RotaTeq® in Preventing Gastroenteritis. [ G1-433]. 46th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy Infectious Diseases Society of America. Washington, DC, 2008.
53. Staat M, Fairbrother G, Edwards K, et al. Delayed onset and diminished magnitude of rotavirus activity. United States, November 2007-May 2008; 2008.
54. Hellard ME, Sinclair MI, Harris AH, et al. Cost of community gastroenteritis. J Gastroenterol Hepatol 2003 18 : 322 8.
55. Wheeler JG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The infectious intestinal disease study executive. BMJ 1999 318 : 1046 50.
56. Harrington M, Butler K, Cafferkey M. Rotavirus infection in hospitalised children: incidence and impact on healthcare resources. Ir J Med Sci 2003 172 : 33 6.
57. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004 13 : 437 52.
58. Metcalfe S, Dougherty S, Brougham M, Moodie P. PHARMAC measures savings elsewhere to the health sector. N Z Med J 2003 116 : U262 3.
59. Vesikari T, Karoven A, Ferrante S, et al. Efficacy of the Pentavalent Rotavirus Vaccine, RotaTeqTM, against Hospitalizations and Emergency Department Visits up to 3 Years Postvaccination: The Finnish Extension Study. 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 2008.